𝔖 Bobbio Scriptorium
✦   LIBER   ✦

KP1019, A New Redox-Active Anticancer Agent – Preclinical Development and Results of a Clinical Phase I Study in Tumor Patients

✍ Scribed by Christian G. Hartinger; Michael A. Jakupec; Stefanie Zorbas-Seifried; Michael Groessl; Alexander Egger; Walter Berger; Haralabos Zorbas; Paul J. Dyson; Bernhard K. Keppler

Publisher
John Wiley and Sons
Year
2008
Tongue
English
Weight
347 KB
Volume
5
Category
Article
ISSN
1612-1872

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

The promising drug candidate indazolium trans‐[tetrachlorobis(1__H__‐indazole)ruthenate(III)] (KP1019) is the second Ru‐based anticancer agent to enter clinical trials. In this review, which is an update of a paper from 2006 (Hartinger et al., J. Inorg. Biochem. 2006, 100, 891–904), the experimental evidence for the proposed mode of action of this coordination compound is discussed, including transport into the cell via the transferrin cycle and activation by reduction. The results of the early clinical development of KP1019 are summarized in which five out of six evaluated patients experienced disease stabilization with no severe side effects.

📜 SIMILAR VOLUMES